Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$38.81 USD
+0.33 (0.86%)
Updated May 31, 2024 04:00 PM ET
After-Market: $38.81 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Brokerage Reports
Arcturus Therapeutics Holdings Inc. [ARCT]
Reports for Purchase
Showing records 101 - 120 ( 140 total )
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Arcturus Enters the COVID-19 Vaccine Race With a Potential Best-in-Class Drug; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Which Orphan Companies to See and Why at Our 32nd Conference
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
New CDO Appointed: With Transition to Clinical Stage Company Imminent; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Part 2: "Must-See" Companies at JPM (Mkt. Cap. $100M-$499M) With 1Q20 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Registration of Ultragenyx Shares Is Stipulated in Agreement; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Dive into the World of LUNAR - Takeaways from Our Call with CEO Joe Payne
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Why You Can''t Miss Our Four Doc Calls on mRNA, PPAR, Hyperoxaluria, Acromegaly
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Keeping up with LNP Delivery: Must Read Takeaways from Our Call with Dr.Cullis
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Join our Two-Part Call Today at 11AM with LNP Expert and ARCT CEO
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Our Holiday Gift: Join Our mRNA, NASH, Acromegaly, Enteric Hyperoxaluria Calls
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Keep Up With LNP Delivery - Join Our Two-Part Call Series on Dec. 2 and 4
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Keep Up With LNP Delivery - Join Our Two-Part Call Series on Dec. 2 and 4
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap Expanding an Already Broad RNA Platform With STARR; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
3Q19 - Using LUNAR, a Novel mRNA STARR is Born
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y